MYGN · Myriad Genetics Inc · Earnings Call Transcripts & Audio
Market Cap
$327.12M
Shares
95.65M
Myriad Genetics Inc Earnings Call Transcripts
Quarterly earnings calls for Myriad Genetics Inc (MYGN), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼6.5%
$156.40M
−$35.10M
'22 Q3
22-11-01
▲10.6%
$177.80M
−$42.30M
'22 Q4
23-02-28
▲9.9%
$181.20M
−$54.70M
'23 Q1
23-05-03
▲2.3%
$183.50M
−$116.10M
'23 Q2
23-08-03
▲22.7%
$191.90M
−$61.30M
'23 Q3
23-11-06
▲10.6%
$196.60M
−$31.20M
'23 Q4
24-01-16
▲11.6%
$202.20M
−$26.00M
'24 Q1
24-05-07
▲15.3%
$211.50M
−$36.70M
'24 Q2
24-08-06
▲11.2%
$213.30M
−$22.10M
'24 Q3
24-10-09
▲7.1%
$210.60M
−$42.50M
'24 Q4
25-01-15
▼3.1%
$195.90M
−$100,000
'25 Q1
25-05-06
▲0.8%
$213.10M
−$330.50M
'25 Q2
25-08-05
▼3.6%
$205.70M
−$27.40M
'25 Q3
25-11-03
▼0.4%
$209.80M
−$7.90M
'25 Q4
26-01-12
▲2.3%
$200.40M
−$34.10M
'26 Q1
26-05-05
LATEST
▼10.5%
$190.70M
−$43.20M
'26 Q2
26-08-04
Conference
Investor event
2026-09-10
Myriad Genetics Inc (MYGN) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Myriad Genetics Inc (MYGN) Q2 2026 Earnings Call Transcript
Cautious tone
Hereditary Cancer (MyRisk) reimbursement pressure
Precise MRD launch and milestones
Hereditary Cancer Testing (MyRisk) volume growth
Revenue
$190.70M
▼ 10.5% YoY Diluted EPS
$-0.46
Gross margin
66.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Myriad Genetics Inc (MYGN) Q1 2026 Earnings Call Transcript
Positive tone
Cancer Care Continuum strategy
Prenatal business decline and FirstGene launch
Commercial team expansion
Revenue
$200.40M
▲ 2.3% YoY Diluted EPS
$-0.36
Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-12
Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Transcript
Positive tone
Precise MRD launch
Prenatal health
MyRisk hereditary cancer testing
Revenue
$209.80M*
▼ 0.4% YoY Gross margin
70.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-03
Myriad Genetics Inc (MYGN) Q3 2025 Earnings Call Transcript
Positive tone
MyRisk hereditary cancer test growth
Financial results and guidance
GeneSight and UnitedHealthcare headwind
Revenue
$205.70M
▼ 3.6% YoY Diluted EPS
$-0.29
Gross margin
69.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Myriad Genetics Inc (MYGN) Q2 2025 Earnings Call Transcript
Confident tone
Prenatal business disruption
Hereditary cancer testing (MyRisk)
Pricing and revenue cycle improvement
Revenue
$213.10M
▲ 0.8% YoY Diluted EPS
$-3.57
Gross margin
71.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Transcript
Cautious tone
GeneSight and UnitedHealthcare headwind
Unaffected hereditary cancer and EMR integration
Prolaris and NCCN positioning
Revenue
$195.90M
▼ 3.1% YoY Diluted EPS
$0.00
Gross margin
68.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-15
Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Transcript
Positive tone
Oncology strategy and continuum of care
PATHOMIQ partnership and AI
Product launches and pipeline
Revenue
$210.60M*
▲ 7.1% YoY Gross margin
71.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-09
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Transcript
Positive tone
GeneSight and UnitedHealthcare policy change
Oncology and MRD opportunity
Hereditary Cancer testing (MyRisk and BRACAnalysis CDx)
Revenue
$213.30M
▲ 11.2% YoY Diluted EPS
$-0.24
Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Myriad Genetics Inc (MYGN) Q2 2024 Earnings Call Transcript
Confident tone
Prenatal / Women's Health
GeneSight and pharmacogenomics
Hereditary cancer testing (MyRisk / BRACAnalysis CDx)
Revenue
$211.50M
▲ 15.3% YoY Diluted EPS
$-0.41
Gross margin
69.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Myriad Genetics Inc (MYGN) Q1 2024 Earnings Call Transcript
Confident tone
Oncology portfolio / Precise Tumor and Liquid
GeneSight
FDA final rule on lab-developed tests
Revenue
$202.20M
▲ 11.6% YoY Diluted EPS
$-0.29
Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-16
Myriad Genetics Inc (MYGN) Q4 2023 Earnings Call Transcript
Confident tone
GeneSight pharmacogenomics
Women's health and hereditary cancer
ASP and reimbursement outlook
Revenue
$196.60M*
▲ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Myriad Genetics Inc (MYGN) Q3 2023 Earnings Call Transcript
Revenue
$191.90M
▲ 22.7% YoY Diluted EPS
$-0.75
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Myriad Genetics Inc (MYGN) Q2 2023 Earnings Call Transcript
Revenue
$183.50M
▲ 2.3% YoY Diluted EPS
$-1.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Myriad Genetics Inc (MYGN) Q1 2023 Earnings Call Transcript
Revenue
$181.20M
▲ 9.9% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Myriad Genetics Inc (MYGN) Q4 2022 Earnings Call Transcript
Revenue
$177.80M*
▲ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Myriad Genetics Inc (MYGN) Q3 2022 Earnings Call Transcript
Revenue
$156.40M
▼ 6.5% YoY Diluted EPS
$-0.43
▼ 243.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Myriad Genetics Inc (MYGN) Q2 2022 Earnings Call Transcript
Revenue
$179.30M
▼ 5.3% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Myriad Genetics Inc (MYGN) Q1 2022 Earnings Call Transcript
Revenue
$164.90M
▼ 4.7% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
Myriad Genetics Inc (MYGN) Q4 2021 Earnings Call Transcript
Revenue
$160.80M*
▲ 4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Myriad Genetics Inc (MYGN) Q3 2021 Earnings Call Transcript
Revenue
$167.30M
▲ 2% YoY Diluted EPS
$0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Myriad Genetics Inc (MYGN) Q2 2021 Earnings Call Transcript
Revenue
$189.40M
▼ 2.9% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Myriad Genetics Inc (MYGN) Q4 2020 Earnings Call Transcript
Revenue
$154.60M
Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Myriad Genetics Inc (MYGN) Q3 2020 Earnings Call Transcript
Revenue
$164.00M
Diluted EPS
$-1.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Myriad Genetics Inc (MYGN) Q2 2020 Earnings Call Transcript
Revenue
$195.10M
▼ 9.4% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Myriad Genetics Inc (MYGN) Q1 2020 Earnings Call Transcript
Revenue
$186.30M
▼ 14% YoY Diluted EPS
$-0.28
▼ 411.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Myriad Genetics Inc (MYGN) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
899923
CUSIP
62855J104
13F (30d)
10 filings
10 filers
Visit website
Investor relations